Abstract: Staphylococcus aureus virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel S. aureus mutants useful in vaccines.
Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The methods comprise administering the optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
Type:
Grant
Filed:
June 22, 2000
Date of Patent:
October 15, 2002
Assignee:
Pharmacia & UpJohn Company
Inventors:
Erik H. F. Wong, Saeeduddin Ahmed, Robert C. Marshall, Robert McArthur, Duncan P. Taylor, Lars Birgerson, Pasquale Cetera
Abstract: Staphylococcus aureus virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel S. aureus mutants useful in vaccines.
Abstract: Antibiotic 10381a1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C1 to C3 alkyl ester of antibiotic 10381a1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
Type:
Grant
Filed:
August 10, 1999
Date of Patent:
May 1, 2001
Assignee:
Pharmacia & Upjohn Company
Inventors:
Alexander D. Argoudelis, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
Abstract: The invention provides methods to identify specific inhibitors of HPV E7 binding to CDK2 and methods to identify specific inhibitors of E7-induced CDK2 kinase activity. Specific inhibitors identified by the methods, compositions comprising the specific inhibitors, and methods of treatment using the compounds are also provided.